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Background: To compare the long-term outcomes of angioplasty (PTA), 
supervised exercise (SEP) and combined treatment (PTA+SEP) in patients 
with intermittent claudication (IC) due to femoropopliteal disease. 
 
Methods: Patients recruited to PTA, SEP and PTA+SEP arms of RCT were 
invited for long-term follow-up from 2010 to 2011.Indicators of limb ischaemia 
were recorded (ankle-brachial pressure indices, treadmill walking distances 
(ICD, MWD, PRWD). Duplex ultrasound was also performed. Patients 
completed SF36 and Vascuqol quality of life(QOL) questionnaires. 
 
Results: Of the 178 patients recruited in the trial, 139 were alive at the time of 
follow-up (PTA=46, SEP=47, PTA+SEP=46). Assessments were completed 
for 111 patients. Median time to follow-up was 5.2years (IQR 3.8-7.4years). 
Median age of patients at follow up was 75years. 62.2%(N=69) of patients 
were symptomatic.16.2%(N= 18) had experienced major cardiovascular event 
since their last follow-up visit. 
Intra-group analysis: Improvement was observed in ankle brachial pressure 
index (ABPI) in all groups. QOL outcomes were inconsistent across individual 
groups.  
Inter-group analysis:  PTA and PTA+SEP groups demonstrated a significantly 
higher ABPI as compared to SEP group. No significant difference was 
observed in walking distances, QOL outcomes, restenosis rates, and new 
ipsilateral and contralateral lesions on duplex scan. Patients required re-
interventions in all group (PTA=14, SEP=10, PTA+SEP=6). Number of re-
interventions was higher in PTA group(N=29) as compared to SEP(N=17) and 
PTA+SEP(N=9) but failed to reach statistical significance. 
 
Conclusion: PTA, SEP and combined treatment are equally effective long-
term treatment options for patients with femoropopliteal claudication. Addition 
of SEP to PTA can reduce the symptomatic restenosis and re-intervention 
rates. 
 




Intermittent claudication (IC) is the commonest presentation of peripheral 
vascular disease that affects 5% of the population over 45 1, 2. Treatment of 
claudication is aimed at improving the quality of life 3. Risk factor modification 
and supervised exercise programmes (SEP) are the first line treatments 
recommended in the most recent treatment guidelines. Percutaneous 
transluminal angioplasty (PTA) and surgery are used in cases where SEP is 
not possible or successful 4, 5. A series of clinical trials have demonstrated no 
difference between the PTA and SEP for clinical outcomes and quality of life 
(QOL) in short term follow up 6, 7. There are only a few studies that report on 
the long term outcomes in these patients 8, 9. This study reports on the long 
term outcomes of one of the largest randomised controlled trials (RCT) 
comparing PTA, SEP and combined treatment (PTA+SEP) in patients with 
intermittent claudication due to femoropopliteal atherosclerotic disease 10-12. 
 
Methods 
The key features of the original trial including design, eligibility, interventions, 
outcome measures and sample size calculation are summarised in Table 1. 
Medical records of all participants who were included in the initial RCT in 2010 
& 2011 were checked to assess their current status of health. All alive patients 
who participated in the initial RCT were contacted via telephone to invite them 
to take part in the long-term follow up visit. All patients who agreed to come 
for follow-up were assessed in the vascular laboratory. Demographic details 
were recorded and a detailed history was obtained including symptoms, risk 
factors, medical comorbidities, smoking status, any cardiovascular problem 
since completion of trial follow-ups, surgery, endovascular intervention and 
amputation. This was cross checked using the clinical and electronic patient 
records to capture all possible adverse events. Patients then underwent a 
fixed load treadmill testing (10-degree inclination and 2.5 km/hour) for a 
maximum of five minutes in accordance with the original trial protocol. Clinical 
indicators of limb ischaemia were recorded including pre and post-exercise 
ankle brachial pressure index, intermittent claudication distance (ICD), 
maximum walking distance (MWD) and the subjective patient reported 
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walking distance (PRWD). Walking distances were measured and recorded in 
metres. The ceiling for MWD for patients who completed the treadmill testing 
without having absolute claudication (AC) was 215 metres. Similarly, the 
ceiling for PRWD was set at 1600 metres (as per the original trial). The 
patients also completed the Version 2.0 of the Short Form 36 (SF36®) 
questionnaire for United Kingdom population for generic quality of life (QOL) 
and Kings College Vascuqol for disease specific QOL in accordance with the 
original trial protocol 13, 14. All patients had an arterial Duplex scan performed 
on both lower limbs and a detailed assessment was undertaken of the whole 
arterial tree to identify new and old lesions.  
The primary outcome measures were MWD and the physical function (PF) 
domain of SF36®.  Secondary outcome measures included pre and post 
exercise ABPI, ICD, PRWD, remaining domains of SF36, Vascuqol, re-
stenosis, re-intervention and major cardiovascular event rates. 
Data Collection was performed on source documents and transcribed onto 
Microsoft® Excel worksheet (Microsoft Corporation, Redmond, Washington, 
USA). Statistical analysis was performed using Stata® 12.0 (StataCorp, 
College Station, Texas, USA) and SPSS® 21.0 (SPSS, Chicago, Illinois, 
USA). Distribution testing for continuous variables was performed using 
histograms. Variables with normal distribution were presented as mean with 
95% confidence interval (CI), whilst skewed variables were represented as 
median with 95%CI and interquartile range (IQR). Hypothesis testing was 
performed for inter-group comparison using Kruskal Wallis ANOVA. 
Categorical variables were compared using Chi square test. Significance level 
was set at 5%. Bonferroni correction was applied for multiple testing in post-
hoc analyses, where applicable. No correction was applied when a single test 
was used for hypothesis testing across the groups. The analysis in the 
primary trial was performed on intention-to-treat basis. This principle was 
followed in the current study and all patients were analysed in the groups they 
were randomised to. However, final analysis was performed on per-protocol 
basis as patients who died prior to follow-up or those who were lost to follow-
up were excluded, as accurate data imputation was not possible due to 
staggered follow-up. 
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Additional approvals were obtained from the trust and local research and 
ethics committee for the long-term follow-up visit as this was not included in 
the original trial protocol (Reference HEY-REF-2424). The follow-up expenses 
were internally funded by the Academic Vascular Surgery Unit of the 




178 patients were recruited in the initial trial. 25% (N=39) had died prior to the 
long term follow-up visit. The follow-up assessments were completed for 
62.3% (N = 111) of the trial patients (CONSORT diagram, Figure 1). Median 
time to long-term follow up was 5.2 years (95%CI 4.6 to 5.7 years, IQR 3.8 to 
7.4 years). Median age of the patients at follow-up was 75 years (95% CI 72 
to 77 years, IQR 68 to 79 years). 62.2% (N = 69) of the patients were 
symptomatic at the time of follow-up. 18.0% (N = 20) of these patients were 
actively smoking at the time of follow up. 16.2% (N = 18) of these patients had 
experienced major cardiovascular event like myocardial infarction, stroke or 
major amputation since their last follow-up visit. Basic demographics, clinical 
status and treadmill testing outcomes at long-term follow up are summarised 
in Table 2. 
 
1) Intra-group analyses 
(a) Clinical indicators of lower limb ischaemia    
No group demonstrated a sustained improvement in MWD. All groups 
demonstrated an improvement in ABPI. However, the improvements in ICD 
and PRWD were not consistently sustained at long term (Table 3).  
 
(b) Quality of life outcomes 
QOL outcomes demonstrated mixed outcomes across the treatment arms. No 
single domain score of the SF36® or Vascuqol score demonstrated 
improvement across all three treatment arms.  (Table 4). 




2) Inter-group analyses  
(a) Clinical indicators of lower limb ischaemia 
Patients in the PTA and the PTA+SEP group demonstrated a significantly 
higher median resting and post-exercise ABPI (RABPI, PABPI) as compared 
to the SEP only patients at long-term follow-up.  However, there was no 
statistically significant difference between the three treatment arms in any 
other clinical indicator (Table 5, Figure 2).  
 
(b) Quality of life outcomes  
No statistically significant difference was observed between the three 
treatment arms in any domain of the SF36 or the Vascuqol score at the long-
term follow-up visit (Table 5, Figure 3 & 4).   
 
3) Re-stenosis and Re-intervention rates 
Arterial duplex ultrasonography was performed in 94.60 % (N=105) of the 
patients who completed the long-term follow up.  A significant stenosis at the 
site of the index lesion (defined as doubling of peak systolic velocity across 
the lesion on duplex scanning) was observed in most of the patients in all 
three treatment arms. New lesions on the same side were detected in two-
thirds of the patients with a similar distribution across the three treatment 
arms. Stenotic lesions on the contralateral side were also detected in all 
treatment arms with relatively higher distribution in the PTA+SEP and the 
SEP only groups as compared to the PTA only group.  The number of patients 
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requiring re-intervention was the lowest in the PTA+SEP arm (N=6); followed 
by the SEP arm (N=10) and the PTA arm (N=14) respectively. Similarly, the 
highest numbers of repeat angioplasty procedures were performed in the PTA 
arm followed by the SEP and the PTA+SEP arms. PTA group also had the 
highest number of surgical revascularisation procedures performed. 
Conversely, PTA+SEP group did not have any surgical revascularisation 
procedures. However, these differences failed to reach the threshold for 
statistical significance (Table 6). 
 
Discussion 
A lack of long-term patient follow-up has always been a problem in the 
previous PAD trials. The long-term outcomes have been reported in one 
previous trial with a small number of patients who completed the follow-up 8. 
Several systematic reviews and meta-analyses have confirmed a dearth of 
evidence as long-term outcomes are seldom reported in RCTs comparing 
angioplasty and the exercise-based treatments for IC 15-17.  The long-term 
follow-up was completed in 80% of patients in this trial who were alive at the 
time of follow-up. This makes it one of the largest series to date reporting on 
these outcomes. Only recently, the long-term outcomes from another trial 
comparing the PTA and the SEP have been published with very similar 
findings to this study 9.  
Twenty-two percent of the trial participants died before the long-term follow-up 
giving an annual mortality rate of four to five percent. This is similar to the 
previously reported rate ranging from five to thirteen percent 18-20. Considering 
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the median age of the deceased, the results of this study support the reported 
reduction in life expectancy of up to ten years in patients with IC 19-21.     
The difference amongst the three treatment arms in the ABPI is similar to 
what was observed at the primary endpoint. Interestingly, it did not have any 
bearing on the walking distances. This observation is contradictory to the 
previous evidence that supports a trend of initial improvement followed by 
some long-term deterioration in due to disease progression and attrition of the 
treatment effect 21-24. Moreover, the PABPI demonstrated a trend of 
continuing improvement in all three treatment arms. The sustained long-term 
improvement in the ABPI at rest and post-exercise in the SEP only treatment 
arm is also a novel finding of this study. Re-interventions may have a strong 
role in producing these trends. However, collateral remodelling may also have 
a part to play. This certainly requires further investigation.       
Although the re-stenosis and re-intervention rates did not show any 
statistically significant difference in the long-term, these findings require 
careful interpretation. Re-stenosis of the primary lesion and new ipsilateral 
lesions on duplex scanning were observed in all treatment arms in a similar 
proportion. Contra-lateral lesions were more prevalent in the SEP and the 
PTA+SEP arms. As ipsilateral and contralateral re-vascularisation procedures 
were more frequent in the PTA arm, it is evident that bilateral symptomatic 
lesions were picked up and treated more frequently in this group. Patients in 
the combined treatment arm (PTA+SEP) had the lowest number of re-
interventions performed with no surgical revascularisation on either side. 
When compared to the PTA+SEP arm, patients required twice as many 
procedures in the SEP arm and three times as many procedures in the PTA 
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arm. The relatively small numbers may account for the lack of statistical 
significance but these findings are highly relevant in the clinical context. 
Addition of SEP to PTA seems to have a lasting effect in preventing an early 
treatment failure with a considerable reduction in the requirement for further 
interventions in the long-term. Further studies are required to investigate the 
long-term difference in re-intervention rates with an appropriate power and 
sample size calculation.           
There are a number of limitations to this study. Firstly, addition of the long-
term follow-up as a protocol exception coupled with staggered recruitment into 
the primary trial, precluded a time fixed long-term follow-up visit. 
Consequently, some patients had a much shorter interval to the follow-up. It 
may be appropriate to consider these results as intermediate to long-term to 
account for this variability. Secondly, the trial was powered to look at a 20% 
difference in primary outcomes at twelve months. As only 62% of the trial 
patients were included in this study, it did not have sufficient power to show a 
statistical difference between groups. Thirdly, the results are applicable to 
femoropopliteal claudicants due to strict inclusion criteria. Fourthly, the time 
cap of five-minutes for fixed-load treadmill testing made it difficult to reach 
absolute claudication, thus limiting the interpretation of results for the ICD and 
the MWD. Recent trials that compared these parameters without time cap 
have demonstrated a significant difference in these outcomes 7, 25. Finally, the 
lack of information regarding actual cause of death for the deceased makes it 
difficult to interpret the true number of cardiovascular events in this cohort. 
This RCT has profound clinical and economic implications for patients with the 
infra-inguinal PAD. It has demonstrated that there is no statistical difference in 
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the short or the long-term outcomes amongst the three treatments. However, 
the differences in re-intervention are clinically relevant and cannot be ignored. 
The new guidelines from the National Institute of Health and Care Excellence 
(NICE) and the American Heart Association (AHA) recommend the SEP as a 
first-line treatment 4, 26. PTA remains a clinically effective first-line treatment 
modality in patients with IC who fail to improve symptomatically with SEP 4, 26-
28. PTA does not confer the additional benefits of lifestyle change, balance 
improvement and motivational therapy 29-31. Addition of SEP to PTA provides 
these benefits and also helps to reduce the number of symptomatic re-
stenoses and re-interventions as shown in this trial. Studies have reported a 
higher incidence of re-interventions following the primary PTA as compared to 
the primary SEP as demonstrated in this trial 9, 32. These findings support the 
provision of the SEP preferentially, prior to offering the PTA as per the recent 
guidelines 4, 26. However, an individual exception has to be made for the 
patients who are unable to take part in an exercise programme due to the co-
morbidities, physical limitation, or a lack of resources for the convenient 
provision of the SEP 33.  
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